All In Biotech

Drug Trial Radar · NCT00911937

A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency

A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Trial To Evaluate The Efficacy And Safety Of A Fesoterodine Flexible Dose Regimen In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency.

Last checked: Nov 20, 2026Latest source record: Dec 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 963 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

963

Actual

Start

Aug 2009

Primary completion

Sep 2011

Study completion Sep 2011

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jun 3, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to assess the efficacy of a flexible dose regimen of fesoterodine on micturition related nocturnal urgency episodes.

Conditions

  • Overactive Bladder

Interventions

  • FesoterodineDrug

    Fesoterodine 4mg and 8 mg tablets taken daily.

  • PlaceboDrug

    Placebo sham 4mg and 8 mg tables taken daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Number of Micturition-related Nocturnal Urgency Episodes Per 24 HoursTime frame: Baseline
  2. Change From Baseline in Mean Number of Micturition-related Nocturnal Urgency Episodes Per 24 Hours at Week 12Time frame: Baseline and Week 12

Locations

112 sites in 1 country. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Mobile, Alabama

  • Pfizer Investigational Site

    Goodyear, Arizona

  • Pfizer Investigational Site

    Litchfield Park, Arizona

  • Pfizer Investigational Site

    Phoenix, Arizona

  • Pfizer Investigational Site

    Tucson, Arizona

  • Pfizer Investigational Site

    Little Rock, Arkansas

  • Pfizer Investigational Site

    Fresno, California

  • Pfizer Investigational Site

    La Mesa, California

  • Pfizer Investigational Site

    Newport Beach, California

  • Pfizer Investigational Site

    Roseville, California

  • Pfizer Investigational Site

    Sacramento, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    Tarzana, California

  • Pfizer Investigational Site

    Denver, Colorado

  • Pfizer Investigational Site

    Denver, Colorado

  • Pfizer Investigational Site

    Farmington, Connecticut

  • Pfizer Investigational Site

    New Britain, Connecticut

  • Pfizer Investigational Site

    Norwalk, Connecticut

  • Pfizer Investigational Site

    Dover, Delaware

  • Pfizer Investigational Site

    Bonita Springs, Florida

  • Pfizer Investigational Site

    Brooksville, Florida

  • Pfizer Investigational Site

    DeFuniak Springs, Florida

  • Pfizer Investigational Site

    Destin, Florida

  • Pfizer Investigational Site

    Leesburg, Florida

  • Pfizer Investigational Site

    Naples, Florida

  • Pfizer Investigational Site

    Ocala, Florida

  • Pfizer Investigational Site

    Ocala, Florida

  • Pfizer Investigational Site

    Pembroke Pines, Florida

  • Pfizer Investigational Site

    South Miami, Florida

  • Pfizer Investigational Site

    St. Petersburg, Florida

  • Pfizer Investigational Site

    Tallahassee, Florida

  • Pfizer Investigational Site

    Tampa, Florida

  • Pfizer Investigational Site

    Atlanta, Georgia

  • Pfizer Investigational Site

    Coeur d'Alene, Idaho

  • Pfizer Investigational Site

    Chicago, Illinois

  • Pfizer Investigational Site

    Chicago, Illinois

  • Pfizer Investigational Site

    Fort Wayne, Indiana

  • Pfizer Investigational Site

    Jeffersonville, Indiana

Showing 40 of 112 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.